menu

At the Crossroad of Care: New Advances in Diabetic Kidney Disease

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

At the Crossroad of Care: New Advances in Diabetic Kidney Disease

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease and end-stage renal disease, accounting for almost 50 percent of all patients starting renal replacement therapy worldwide. At least half of the patients with T2DM will develop diabetic kidney disease (DKD). DKD is the single strongest predictor of morbidity and premature mortality in patients with diabetes. Even mild increases in albuminuria or GFR decline are associated with an increased risk of cardiovascular diseases and CV death, along with increased health-care costs. Therefore, kidney protection is a critical target in T2DM. Join us as we take a look at new therapeutic agents for the prevention of DKD development and progression.

  • Disclosure of Conflicts of Interest

    According to the disclosure policy of the University of Cincinnati College of Medicine, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity.  All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati College of Medicine to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

    The following faculty has reported real or apparent conflicts of interest that have been resolved:

    Janet McGill, MD has disclosed the following relevant financial relationships:
    Consultant: Bayer, Boehringer Ingelheim, Dexcom, Salix
    Advisory Board Member: Bayer, Boehringer Ingelheim, Dexcom, Lilly, Metavant
    Grant Research: Dexom, Medtronic, Novo Nordisk

    John J. Russell, MD (host) has disclosed the following relevant financial relationships: 
    Consultant and Advisory Board Member: GlaxoSmithKline
    Speaker and Advisory Board Member: Sanofi

    The following reviewers/planners/authors have reported real or apparent conflicts of interest:

    Susan Tyler, PhD, CMP, CHCP, CME Director, has nothing to disclose.
    Bruce Gebhardt, MD, CME Reviewer, has nothing to disclose.
    Heather Muskopf, Program Manager, has nothing to disclose.
    Otto Ratz, MD, has nothing to disclose.
    Christina Culbert, MSc, has nothing to disclose.

  • Target Audience

    This continuing medical education (CME) activity is intended for physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with diabetic kidney disease.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Develop a framework for evaluation of glycemic control to delay or prevent the onset and progression of DKD;
    • Assess the clinical data of newer and emerging treatments providing reno-cardiovascular protection for patients with DKD;
    • Recognize the management of DKD necessitates a multifactorial approach, beyond medical therapy, that includes fostering an effective patient-provider relationship to optimize outcomes.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Provider
    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    This program is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc., Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease and end-stage renal disease, accounting for almost 50 percent of all patients starting renal replacement therapy worldwide. At least half of the patients with T2DM will develop diabetic kidney disease (DKD). DKD is the single strongest predictor of morbidity and premature mortality in patients with diabetes. Even mild increases in albuminuria or GFR decline are associated with an increased risk of cardiovascular diseases and CV death, along with increased health-care costs. Therefore, kidney protection is a critical target in T2DM. Join us as we take a look at new therapeutic agents for the prevention of DKD development and progression.

  • Disclosure of Conflicts of Interest

    According to the disclosure policy of the University of Cincinnati College of Medicine, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity.  All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati College of Medicine to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

    The following faculty has reported real or apparent conflicts of interest that have been resolved:

    Janet McGill, MD has disclosed the following relevant financial relationships:
    Consultant: Bayer, Boehringer Ingelheim, Dexcom, Salix
    Advisory Board Member: Bayer, Boehringer Ingelheim, Dexcom, Lilly, Metavant
    Grant Research: Dexom, Medtronic, Novo Nordisk

    John J. Russell, MD (host) has disclosed the following relevant financial relationships: 
    Consultant and Advisory Board Member: GlaxoSmithKline
    Speaker and Advisory Board Member: Sanofi

    The following reviewers/planners/authors have reported real or apparent conflicts of interest:

    Susan Tyler, PhD, CMP, CHCP, CME Director, has nothing to disclose.
    Bruce Gebhardt, MD, CME Reviewer, has nothing to disclose.
    Heather Muskopf, Program Manager, has nothing to disclose.
    Otto Ratz, MD, has nothing to disclose.
    Christina Culbert, MSc, has nothing to disclose.

  • Target Audience

    This continuing medical education (CME) activity is intended for physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with diabetic kidney disease.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Develop a framework for evaluation of glycemic control to delay or prevent the onset and progression of DKD;
    • Assess the clinical data of newer and emerging treatments providing reno-cardiovascular protection for patients with DKD;
    • Recognize the management of DKD necessitates a multifactorial approach, beyond medical therapy, that includes fostering an effective patient-provider relationship to optimize outcomes.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Provider
    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    This program is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc., Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule30 Nov 2021
Webpack App